bill & melinda gates foundation - ken duncan
DESCRIPTION
Partnerships in drug discovery and development for diseases of the developing worldTRANSCRIPT
Partnerships in drug discovery and development for diseases of the developing world
Ken DuncanBioDundee, Dundee29 May, 2013
2
TOPICS
1. Introduction to the work of the Bill & Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug discovery and development
3
TOPICS
1. Introduction to the work of the Bill & Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug discovery and development
© 2010 Bill & Melinda Gates Foundation |
Our Belief
ALL LIVES—NO MATTER WHERE THEY ARE BEING LIVED—
HAVE EQUAL VALUE
Our History
Bill and Melindaread an articleabout rotavirus
They officially create the foundation
Warren Buffettdecides to
give BerkshireHathaway stock
1998 2000 2006 2008
Bill joins Melindafull-time at the
foundation
$36.4 billionAsset trust endowment
$26 billionGrants Since inception
1,100Employees worldwide
$3.4 billion2012 grants payments
$31.3 billionWarren Buffet pledge
Headquarters: Seattle
Offices: London, Washington DC
Country Offices: China, India
Country Representatives: Ethiopia, South Africa, Nigeria
Reach & Presence
What We Focus On
What are the areas
of greatest need?
Where can we have
the greatest impact?
United States
Program
Global Health Program
Global Development
Program
Programs
2011 Grants Paid Summary
For the year ended December 31, 2011. Amount in thousands.
(by Program Area)
Global Health $1,977,507
Global Development $667,780
United States Program $486,917
Operations/Non-Program Grants $48,466
Strategic Media Partnerships $18,379
Policy & Government Affairs $9,117
Integrated Approach for Global Health
VACCINES
VECTOR CONTROL
SANITATION
FAMILY HEALTH
DRUGS
DIAGNOSTICS
How Our Strategies Align
All strategies seek transformational change.
All strategies rely on partners and grantees to carry out the work.
All strategies emphasize technology.
TOPICS
1. Introduction to the work of the Bill & Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug discovery and development
Drug discovery priorities
Malaria Helminths
Diarrheal Disease
TB
Platforms
Drug discovery priorities
Malaria
Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP(Single Encounter Radical Cure and
Prophylaxis)
Target Product Profile
Drug discovery priorities
Helminths
Onchocerciasis: "River Blindness"Onchocerciasis: "River Blindness"
Lymphatic Filariasis: "Elephantiasis"Lymphatic Filariasis: "Elephantiasis"
Macrofilaricide
Kill Adult wormsSafe in Loa loa regions
Target Product Profile
Drug discovery priorities
TB
Novel combination
Shorter, safer treatmentOvercome MDR-TB
Target Product Profile
Drug discovery priorities
Diarrheal Disease
Adapted from The Global Burden of Disease: 2004 Update; WHO
Anti-secretory
Boost ORS effectivenessIncrease ORS compliance
Target Product Profile
Drug discovery priorities
Platforms
Grantees and partnersTarget Lead Candidate
LeadOptimisation
Targetvalidation
Pre-clinical ClinicalDevelopment
LeadIdentification
Targetidentification
Product Development Partnerships
Academia, Institutes
Pharma
Biotech
TOPICS
1. Introduction to the work of the Bill & Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of partnerships in TB drug discovery and development
TB treatment today
6-24 months
Multiple drugs
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Complexity: DOTS
Safety, drug-drug interactions
The World needs a shorter, safer drug regimen
Bedaquiline, first new TB drug approved in over 40 years
December 31, 2012
Importance of Partnerships
Target Lead Candidate
LeadOptimisation
Targetvalidation
Pre-clinical ClinicalDevelopment
LeadIdentification
Targetidentification
TBDA
CPTR
24
CPTR: A new development paradigm
TBDA
Next generation therapy
Goal:A new first line drug regimen that works in one month or less
Problem:Few new drug candidates, little diversity
Solution:An integrated cross-industry-academia discovery partnership
Challenge:
TBDA
The TBDA is a groundbreaking partnership between seven pharmaceutical companies and six research institutions collaborating on early TB drug discovery
The TB Drug Accelerator
How it works…
Company Compound
Libraries
Collaborative Discovery Research 5 new preclinical candidates
2016
1 month regimenproof of concept
2021
• Hit and Lead Generation• Target Identification
• Lead Optimization
Research Institutions: Pharmaceutical Companies: With support from:
TBDA
The TBDA is a New Paradigm For Drug Discovery
The TBDA offers a new approach that addresses many of the bottlenecks in the way TB drugs are currently developed
ONLY THE BEST CANDIDATES ADVANCE
Early Collaboration
Avoid Redundancy
Data Sharing
MaximizeEfficiency
Overcome Competitive
Barriers
Companies Work on Each Other’s
Compounds
TBDA
• Partnerships such as the TBDA show how industry and others can work together in new ways to support global health innovation
• The TBDA model could be applied to other disease areas that lack incentives for research or require combination drug therapies
The TBDA Offers a Model for Other Initiatives
EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.
All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries.
Learn Morewww.GatesFoundation.org
www.ImpatientOptimists.org
BillandMelindaGatesFoundation
@GatesFoundation